Supplementary Figure S3 from Predictive and Prognostic Implications of Circulating CX3CR1<sup>+</sup> CD8<sup>+</sup> T Cells in Non–Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy

Eihab Abdelfatah,Mark D. Long,Ryutaro Kajihara,Takaaki Oba,Takayoshi Yamauchi,Hongbin Chen,Joy Sarkar,Kristopher Attwood,Junko Matsuzaki,Brahm H. Segal,Grace K. Dy,Fumito Ito

crossref（2023）

引用 0|浏览17

暂无评分

摘要

Supplementary Figure 3. An increase of the CX3CR1 score is associated with better survival in NSCLC patients undergoing chemo-immunotherapy. Related to Fig. 1E Progression free survival (PFS) and overall survival (OS) for high (≥ 20%) versus low (< 20%) CX3CR1 score. P values were calculated by a log-rank (Mantel-Cox) test.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Supplementary Figure S3 from Predictive and Prognostic Implications of Circulating CX3CR1&lt;sup&gt;+&lt;/sup&gt; CD8&lt;sup&gt;+&lt;/sup&gt; T Cells in Non–Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy

Supplementary Figure S3 from Predictive and Prognostic Implications of Circulating CX3CR1<sup>+</sup> CD8<sup>+</sup> T Cells in Non–Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy